SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 216 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q2 2016. The put-call ratio across all filers is 0.76 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2017 | $1,293,000 | -82.0% | 30,000 | -87.0% | 0.19% | -83.7% |
| Q1 2017 | $7,199,000 | +14.0% | 230,000 | -8.0% | 1.14% | -5.8% |
| Q4 2016 | $6,313,000 | -99.9% | 250,000 | -7.4% | 1.21% | +14.0% |
| Q3 2016 | $6,677,100,000 | +116960.0% | 270,000 | -3.6% | 1.06% | +4.7% |
| Q2 2016 | $5,704,000 | +38.5% | 280,000 | +3.7% | 1.01% | +24.0% |
| Q1 2016 | $4,118,000 | +6.4% | 270,000 | -6.2% | 0.82% | +39.7% |
| Q4 2015 | $3,871,000 | -21.9% | 288,000 | -18.5% | 0.58% | -25.9% |
| Q3 2015 | $4,957,000 | -30.0% | 353,328 | -15.3% | 0.79% | -7.1% |
| Q2 2015 | $7,081,000 | +29.9% | 417,000 | -7.5% | 0.85% | -7.5% |
| Q1 2015 | $5,450,000 | +161.8% | 450,800 | +79.7% | 0.92% | +52.4% |
| Q4 2014 | $2,082,000 | +13.0% | 250,800 | +18.3% | 0.60% | +11.9% |
| Q3 2014 | $1,842,000 | -25.9% | 212,000 | -6.6% | 0.54% | -27.0% |
| Q2 2014 | $2,486,000 | +41.5% | 227,000 | +15.5% | 0.74% | +40.0% |
| Q1 2014 | $1,757,000 | +3.5% | 196,537 | -12.7% | 0.53% | -20.6% |
| Q4 2013 | $1,697,000 | – | 225,000 | – | 0.66% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 297,500 | $17,478,000 | 3.94% |
| ASHFORD CAPITAL MANAGEMENT INC | 1,124,405 | $36,341,000 | 3.91% |
| ARMISTICE CAPITAL, LLC | 3,100,000 | $100,192,000 | 1.94% |
| S&T BANK/PA | 316,326 | $10,224,000 | 1.54% |
| Bruce & Co., Inc. | 222,105 | $7,178,000 | 1.47% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 379,875 | $12,278,000 | 1.36% |
| RICE HALL JAMES & ASSOCIATES, LLC | 854,949 | $27,632,000 | 1.10% |
| Soleus Capital Management, L.P. | 251,000 | $8,112,000 | 1.05% |
| Parkman Healthcare Partners LLC | 108,954 | $3,521,000 | 1.03% |
| Aristotle Capital Boston, LLC | 1,258,067 | $40,661,000 | 1.03% |